Country: Ավստրալիա
language: անգլերեն
source: Department of Health (Therapeutic Goods Administration)
isavuconazonium sulfate, Quantity: 186.3 mg (Equivalent: isavuconazole, Qty 100 mg)
Pfizer Australia Pty Ltd
Capsule
Excipient Ingredients: potassium acetate; gellan gum; iron oxide red; sodium lauryl sulfate; titanium dioxide; hypromellose; disodium edetate; magnesium citrate; microcrystalline cellulose; purified talc; colloidal anhydrous silica; stearic acid; propylene glycol; butan-1-ol; purified water; isopropyl alcohol; Shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide
Oral
14
(S4) Prescription Only Medicine
CRESEMBA is indicated in adults for the treatment of ? invasive aspergillosis ? mucormycosis in patients for whom amphotericin B is inappropriate (see Section 4.4 Special warnings and precautions for use and Section 5.1 Pharmacodynamic properties),Consideration should be given to official guidance on the appropriate use of antifungal agents.
Visual Identification: Swedish Orange (reddish-brown) capsule body marked with 100 in black ink and a white cap marked with C in black ink.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2019-05-17
CRESEMBA ® C R E S E M B A ® CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ▼ This medicine is new or being used differently. Please report side effects. See the full CMI for further details. 1. WHY AM I USING CRESEMBA? CRESEMBA contains the active ingredient isavuconazole. CRESEMBA is used to treat fungal infections such as invasive aspergillosis and invasive mucormycosis. This medicine works by preventing the growth of the fungal organisms causing your infection. For more information, see Section 1. Why am I using CRESEMBA? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE CRESEMBA? Do not use if you have ever had an allergic reaction to isavuconazole or any of the ingredients listed at the end of the CMI, or any other similar medicines such as ketoconazole, fluconazole, itraconazole, voriconazole or posaconazole. Do not use CRESEMBA if you are taking any of the medicine listed in section 3. What if I am taking other medicines? Do not take this medicine if you have familial short QT syndrome (Disorder of the heart). CRESEMBA should not be taken during pregnancy or breastfeeding, unless indicated by your doctor. Effective contraception should be used in woman of childbearing potential. Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding. For more information, see Section 2. What should I know before I use CRESEMBA? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with CRESEMBA and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE CRESEMBA? CRESEMBA is available as capsules for oral use or as an IV powder for injection. CRESEMBA capsules should be swallowed whole with a full glass of water. Do not chew, crush, dissolve or open the capsules. CRESEMBA IV Injection is read_full_document
Version : pfpcrema10922 Supersedes: pfpcrema10122 Page 1 of 28 This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems. AUSTRALIAN PRODUCT INFORMATION – CRESEMBA® (ISAVUCONAZOLE) POWDER FOR INJECTION AND CAPSULES 1. NAME OF THE MEDICINE Isavuconazole (as isavuconazonium sulfate). 2. QUALITATIVE AND QUANTITATIVE COMPOSITION POWDER FOR INJECTION Each vial contains 200 mg isavuconazole (as 372.6 mg isavuconazonium sulfate). CAPSULES Each capsule contains 100 mg isavuconazole (as 186.3 mg isavuconazonium sulfate). For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM POWDER FOR INJECTION Powder for injection; white to yellow powder for intravenous administration following reconstitution and dilution. CAPSULES Swedish Orange (reddish-brown) capsule body marked with “100” in black ink and a white cap marked with “C” in black ink. For oral administration. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS CRESEMBA is indicated in adults for the treatment of • invasive aspergillosis • mucormycosis in patients for whom amphotericin B is inappropriate (see Section 4.4 Special warnings and precautions for use and Section 5.1 Pharmacodynamic properties) Consideration should be given to official guidance on the appropriate use of antifungal agents. ▼ Version : pfpcrema10922 Supersedes: pfpcrema10122 Page 2 of 28 4.2 DOSE AND METHOD OF ADMINISTRATION DOSAGE Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly. The recommended loading and maintenance dose for both the powder for injection and capsule formulations are shown in Table 1 below. TABLE 1. DOSAGE REGIMEN FOR CRESEMBA LOADING DOSE MAINTENANCE DOSE A CRESEMBA Powder for injection ( read_full_document